Suppr超能文献

非血液学系统肥大细胞增多症的诊断:放射学与病理学的合作。

Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology.

机构信息

Department of Radiology, University of Minnesota Medical Center, Minneapolis, MN, USA.

Division of Hematology, Stanford Cancer Institute, Stanford University School of Medicine, CA, USA.

出版信息

Blood Rev. 2021 Jan;45:100693. doi: 10.1016/j.blre.2020.100693. Epub 2020 Apr 8.

Abstract

Systemic mastocytosis (SM) is a hematologic disease with a wide range of clinical courses ranging from an indolent condition with normal life expectancy to exceedingly aggressive disorder with a poor prognosis. The symptoms and signs of SM result from the release of mast cell mediators with heterogeneous functions, and/or organ damage from neoplastic mast cell infiltration, or both. Diagnostic criteria for SM are well-defined by the World Health Organization (WHO). However, the diagnosis of SM can be difficult when especially it is not in the differential diagnosis. Routinely used radiologic techniques (e.g., X-ray, ultrasound, CT scans can show findings such as lytic-, sclerotic- or mixed-bone lesions, splenomegaly, hepatomegaly, retroperitoneal or periportal mesenteric lymphadenopathy, and omental thickening). It is essential to emphasize that the constellation of these radiologic findings should strongly concern of SM, especially in patients who also have a skin rash, allergic reactions, gastrointestinal tract symptoms (lasting, intermittent nausea, diarrhea), paroxysmal tachycardias, unexplained weight loss, persistent bone pain, cytopenias, liver dysfunction, eosinophilia. These findings, even coincidentally noted, will likely lead to a tissue biopsy, which reveals diagnosis (as we discussed and illustrated some tissue biopsies here). Moreover, the role of MRI and new techniques such as [18-fluorodeoxyglucose positron emission computed tomography, fibroscan] in the diagnosis of SM have been discussed. Furthermore, we reviewed the use of radiologic methods to evaluate treatment response and prognostication of SM..

摘要

系统性肥大细胞增多症(SM)是一种血液疾病,其临床表现广泛,从预期寿命正常的惰性疾病到预后不良的侵袭性疾病。SM 的症状和体征是由于肥大细胞介质的释放引起的,这些介质具有不同的功能,和/或肿瘤性肥大细胞浸润引起的器官损伤,或两者兼有。SM 的诊断标准由世界卫生组织(WHO)明确界定。然而,当 SM 不在鉴别诊断中时,其诊断可能会很困难。常规使用的影像学技术(例如 X 射线、超声、CT 扫描)可以显示溶骨性、硬化性或混合性骨病变、脾肿大、肝肿大、腹膜后或门静脉肠系膜淋巴结病和大网膜增厚等发现。必须强调的是,这些影像学发现的组合应强烈怀疑 SM,特别是在患者也有皮疹、过敏反应、胃肠道症状(持续、间歇性恶心、腹泻)、阵发性心动过速、不明原因体重减轻、持续性骨痛、血细胞减少、肝功能异常、嗜酸性粒细胞增多的情况下。即使偶然发现这些发现,也可能会导致进行组织活检,从而做出诊断(正如我们在这里讨论和说明了一些组织活检)。此外,还讨论了 MRI 和新技术(如[18-氟脱氧葡萄糖正电子发射断层扫描、纤维扫描])在 SM 诊断中的作用。此外,我们还回顾了放射学方法在评估 SM 治疗反应和预后中的应用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验